<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339853</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>AP3B1 Has Type I Interferon-Independent Antiviral Function against SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1377</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091377</ELocationID><Abstract><AbstractText>The unprecedented research effort associated with the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) included several extensive proteomic studies that identified host proteins that interact with individual viral gene products. However, in most cases, the consequences of those virus-host interactions for virus replication were not experimentally pursued, which is a necessary step in determining whether the interactions represent pro- or anti-viral events. One putative interaction commonly identified in multiple studies was between the host adaptor protein complex 3 (AP-3) subunit B1 (AP3B1) and the SARS-CoV-2 envelope protein (E). AP3B1 is one subunit of AP-3 required for the biogenesis of lysosomal-related organelles (LROs), and its function impacts important disease processes including inflammation and vascular health. Thus, interactions between AP3B1 and SARS-CoV-2 might influence the clinical outcomes of infection. To determine if AP3B1 has a role in the SARS-CoV-2 replication cycle, we first confirmed the interaction in virus-infected cells using immunoprecipitation (IP) and immunofluorescence assays (IFA). AP3B1 is required by multiple viruses to aid in the replication cycle and therefore may be a therapeutic target. However, we found that the overexpression of AP3B1 suppressed SARS-CoV-2 replication, whereas the siRNA-mediated depletion of AP3B1 increased the release of infectious virus, suggesting an antiviral role for AP3B1. Together, our findings suggest that AP3B1 is an intrinsic barrier to SARS-CoV-2 replication through interactions with the viral E protein. Our work justifies further investigations of LRO trafficking in SARS-CoV-2 target cells and their role in viral pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Gayatri</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5506-9609</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hage</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7668-892X</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldmann</LastName><ForeName>Friederike</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiramel</LastName><ForeName>Abhilash I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNally</LastName><ForeName>Kristin L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturdevant</LastName><ForeName>Gail L</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0001-9653-9008</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beare</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Best</LastName><ForeName>Sonja M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1ZIAAI001125-04</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033963">Adaptor Protein Complex 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033966">Adaptor Protein Complex beta Subunits</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033963" MajorTopicYN="Y">Adaptor Protein Complex 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033966" MajorTopicYN="N">Adaptor Protein Complex beta Subunits</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AP3B1</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral proteins</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339853</ArticleId><ArticleId IdType="pmc">PMC11437497</ArticleId><ArticleId IdType="doi">10.3390/v16091377</ArticleId><ArticleId IdType="pii">v16091377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H., Jureka A.S., Obernier K., Guo J.Z., Batra J., et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;370:eabe9403. doi: 10.1126/science.abe9403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9403</ArticleId><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O’Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.H., Sanchez-Rivera F.J., Schneider W.M., Luna J.M., Soto-Feliciano Y.M., Ashbrook A.W., Le Pen J., Leal A.A., Ricardo-Lax I., Michailidis E., et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host Microbe. 2021;29:267–280.e265. doi: 10.1016/j.chom.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7833927</ArticleId><ArticleId IdType="pubmed">33357464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S., Dellibovi-Ragheb T.A., Kerviel A., Pak E., Qiu Q., Fisher M., Takvorian P.M., Bleck C., Hsu V.W., Fehr A.R., et al. beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. Cell. 2020;183:1520–1535.e1514. doi: 10.1016/j.cell.2020.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.039</ArticleId><ArticleId IdType="pmc">PMC7590812</ArticleId><ArticleId IdType="pubmed">33157038</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.Y., Guo X. Adaptor protein complexes and intracellular transport. Biosci. Rep. 2014;34:e00123. doi: 10.1042/BSR20140069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20140069</ArticleId><ArticleId IdType="pmc">PMC4114066</ArticleId><ArticleId IdType="pubmed">24975939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanger A., Hirst J., Davies A.K., Robinson M.S. Adaptor protein complexes and disease at a glance. J. Cell Sci. 2019;132:jcs222992. doi: 10.1242/jcs.222992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.222992</ArticleId><ArticleId IdType="pubmed">31636158</ArticleId></ArticleIdList></Reference><Reference><Citation>Banushi B., Simpson F. Overlapping Machinery in Lysosome-Related Organelle Trafficking: A Lesson from Rare Multisystem Disorders. Cells. 2022;11:3702. doi: 10.3390/cells11223702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11223702</ArticleId><ArticleId IdType="pmc">PMC9688865</ArticleId><ArticleId IdType="pubmed">36429129</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampini E., Schillemans M., Hofman M., van Alphen F., de Boer M., Kuijpers T.W., van den Biggelaar M., Voorberg J., Bierings R. Defective AP-3-dependent VAMP8 trafficking impairs Weibel-Palade body exocytosis in Hermansky-Pudlak Syndrome type 2 blood outgrowth endothelial cells. Haematologica. 2019;104:2091–2099. doi: 10.3324/haematol.2018.207787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.207787</ArticleId><ArticleId IdType="pmc">PMC6886443</ArticleId><ArticleId IdType="pubmed">30630984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., Zhu L., Huang L., Zhou J. Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis. Int. J. Hematol. 2015;102:488–492. doi: 10.1007/s12185-015-1807-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-015-1807-z</ArticleId><ArticleId IdType="pubmed">25980904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryce C., Grimes Z., Pujadas E., Ahuja S., Beasley M.B., Albrecht R., Hernandez T., Stock A., Zhao Z., AlRasheed M.R., et al. Pathophysiology of SARS-CoV-2: The Mount Sinai COVID-19 autopsy experience. Mod. Pathol. 2021;34:1456–1467. doi: 10.1038/s41379-021-00793-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00793-y</ArticleId><ArticleId IdType="pmc">PMC8015313</ArticleId><ArticleId IdType="pubmed">33795830</ArticleId></ArticleIdList></Reference><Reference><Citation>Strazic Geljic I., Kucan Brlic P., Musak L., Karner D., Ambriovic-Ristov A., Jonjic S., Schu P., Rovis T.L. Viral Interactions with Adaptor-Protein Complexes: A Ubiquitous Trait among Viral Species. Int. J. Mol. Sci. 2021;22:5274. doi: 10.3390/ijms22105274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22105274</ArticleId><ArticleId IdType="pmc">PMC8156722</ArticleId><ArticleId IdType="pubmed">34067854</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo C., Burton A., Ruiz-Mateos E., Marsh M., Saiardi A. Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release. Proc. Natl. Acad. Sci. USA. 2009;106:21161–21166. doi: 10.1073/pnas.0909176106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909176106</ArticleId><ArticleId IdType="pmc">PMC2795533</ArticleId><ArticleId IdType="pubmed">19934039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., McCrory T.S., Khaw W.Y., Petzing S., Myers T., Schmitt A.P. Matrix proteins of Nipah and Hendra viruses interact with beta subunits of AP-3 complexes. J. Virol. 2014;88:13099–13110. doi: 10.1128/JVI.02103-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02103-14</ArticleId><ArticleId IdType="pmc">PMC4249102</ArticleId><ArticleId IdType="pubmed">25210190</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal T., Schu P., Medigeshi G.R. Adaptor protein complexes-1 and 3 are involved at distinct stages of flavivirus life-cycle. Sci. Rep. 2013;3:1813. doi: 10.1038/srep01813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01813</ArticleId><ArticleId IdType="pmc">PMC3648799</ArticleId><ArticleId IdType="pubmed">23657274</ArticleId></ArticleIdList></Reference><Reference><Citation>Scroggs S.L.P., Offerdahl D.K., Flather D.P., Morris C.N., Kendall B.L., Broeckel R.M., Beare P.A., Bloom M.E. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV. Viruses. 2020;13:8. doi: 10.3390/v13010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010008</ArticleId><ArticleId IdType="pmc">PMC7822115</ArticleId><ArticleId IdType="pubmed">33374514</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura K., Suzuki Y., Ishida K., Arakawa M., Wu H., Fujioka Y., Emi A., Maeda K., Hamajima R., Nakano T., et al. Distinct motifs in the E protein are required for SARS-CoV-2 virus particle formation and lysosomal deacidification in host cells. J. Virol. 2023;97:e0042623. doi: 10.1128/jvi.00426-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00426-23</ArticleId><ArticleId IdType="pmc">PMC10617393</ArticleId><ArticleId IdType="pubmed">37830820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zheng Q., Sun L., Ji M., Li Y., Deng H., Zhang H. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev. Cell. 2021;56:3250–3263.e3255. doi: 10.1016/j.devcel.2021.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8502680</ArticleId><ArticleId IdType="pubmed">34706264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson G.J., Mears H.V., Broncel M., Snijders A.P., Bauer D.L.V., Carlton J.G. ER-export and ARFRP1/AP-1-dependent delivery of SARS-CoV-2 Envelope to lysosomes controls late stages of viral replication. Sci. Adv. 2024;10:eadl5012. doi: 10.1126/sciadv.adl5012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adl5012</ArticleId><ArticleId IdType="pmc">PMC10990277</ArticleId><ArticleId IdType="pubmed">38569033</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Sutton J., Woodruff E., Villalta F., Spearman P., Dong X. Defective HIV-1 particle assembly in AP-3-deficient cells derived from patients with Hermansky-Pudlak syndrome type 2. J. Virol. 2012;86:11242–11253. doi: 10.1128/JVI.00544-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00544-12</ArticleId><ArticleId IdType="pmc">PMC3457180</ArticleId><ArticleId IdType="pubmed">22875976</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Li H., Derdowski A., Ding L., Burnett A., Chen X., Peters T.R., Dermody T.S., Woodruff E., Wang J.J., et al. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell. 2005;120:663–674. doi: 10.1016/j.cell.2004.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.12.023</ArticleId><ArticleId IdType="pubmed">15766529</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchenko A.K., Zhernakova D.V., Malov S.V., Komissarov A., Kolchanova S.M., Tamazian G., Antonik A., Cherkasov N., Kliver S., Turenko A., et al. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population. Proc. Natl. Acad. Sci. USA. 2021;118:e2107830118. doi: 10.1073/pnas.2107830118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2107830118</ArticleId><ArticleId IdType="pmc">PMC8672799</ArticleId><ArticleId IdType="pubmed">34782459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kook S., Wang P., Meng S., Jetter C.S., Sucre J.M.S., Benjamin J.T., Gokey J.J., Hanby H.A., Jaume A., Goetzl L., et al. AP-3-dependent targeting of flippase ATP8A1 to lamellar bodies suppresses activation of YAP in alveolar epithelial type 2 cells. Proc. Natl. Acad. Sci. USA. 2021;118:e2025208118. doi: 10.1073/pnas.2025208118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025208118</ArticleId><ArticleId IdType="pmc">PMC8157957</ArticleId><ArticleId IdType="pubmed">33990468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortmann S.D., Patton M.J., Frey B.F., Tipper J.L., Reddy S.B., Vieira C.P., Hanumanthu V.S., Sterrett S., Floyd J.L., Prasad R., et al. Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19. Blood Adv. 2023;7:4200–4214. doi: 10.1182/bloodadvances.2022009022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022009022</ArticleId><ArticleId IdType="pmc">PMC10022176</ArticleId><ArticleId IdType="pubmed">36920790</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023;44:695–709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Liu D., Liu W., Wang G., Chen L., Cao Y., Wei J., Xiao M., Liu X., Huang G., et al. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. Eur. J. Hum. Genet. 2021;29:1312–1315. doi: 10.1038/s41431-021-00886-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-021-00886-x</ArticleId><ArticleId IdType="pmc">PMC8053565</ArticleId><ArticleId IdType="pubmed">33867526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>